ocriplasmin
Trade name: jetrea
Approved
Oct 17, 2012
Ocriplasmin, sold under the brand name Jetrea, is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface. It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012. It works by dissolving the proteins that link the vitreous to the macula, resulting in posterior detachment of the vitreous from the retina. — Wikipedia
Clinical trial activity
24 trials · 14 clinical orgs · 1 marketing orgs
Earliest trial started Dec 1, 2004 (NCT00123279)
Timeline
2000s
- Jan 1, 2004
Oxurion NV. — Earliest Phase 2 Sponsor(trial)
- Jan 1, 2008
Earliest Phase 3 Sponsor(trial)
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
- Oct 17, 2012
Oxurion NV. — Earliest FDA Approval
- Oct 17, 2012
Oxurion NV. — Marketing Organization
- Oct 17, 2012
Oxurion NV. — NDA Organization
Indications
Approved for
Studied for
- Arterial Occlusive Diseases · Phase 2
- Diabetic Retinopathy · Phase 3
- Disease Progression · Phase 2
- Eye Diseases · Phase 2
- Macular Degeneration · Phase 2
- Macular Edema · Phase 2
- Retinal Vein Occlusion · Phase 1
- Stroke · Phase 2
- Tissue Adhesions · Phase 4
- Uveitis · Phase 1/Phase 2
- Venous Thrombosis · Phase 2
- Vitrectomy · Phase 2
- Vitreous Body · Phase 4
- Vitreous Detachment · Phase 2
Mechanism of action
- CollagenHYDROLYTIC ENZYME
Collagen hydrolytic enzyme
It's a recombinant truncated form of human plasmin with proteolytic activity against protein components of the vitreous body and the vitreoretinal interface
- Collagen alpha-2(I) chain (COL1A2) ↗
- Collagen alpha-1(I) chain (COL1A1) ↗
- Collagen alpha-1(II) chain (COL2A1) ↗
- Collagen alpha-1(III) chain (COL3A1) ↗
- Collagen alpha-1(IV) chain (COL4A1) ↗
- Collagen alpha-1(V) chain (COL5A1) ↗
- Collagen alpha-1(VI) chain (COL6A1) ↗
- Collagen alpha-1(XI) chain (COL11A1) ↗
- Collagen alpha-1(XV) chain (COL15A1) ↗
- Collagen alpha-1(XVIII) chain (COL18A1) ↗
- Collagen alpha-1(XXIV) chain (COL24A1) ↗
- Collagen alpha-1(XXVII) chain (COL27A1) ↗
- Collagen alpha-1(XXVIII) chain (COL28A1) ↗
- Collagen alpha-2(IV) chain (COL4A2) ↗
- Collagen alpha-2(V) chain (COL5A2) ↗
- Collagen alpha-2(VI) chain (COL6A2) ↗
- Collagen alpha-2(XI) chain (COL11A2) ↗
- Collagen alpha-3(IV) chain (COL4A3) ↗
- Collagen alpha-3(V) chain (COL5A3) ↗
- Collagen alpha-3(VI) chain (COL6A3) ↗
- Collagen alpha-4(IV) chain (COL4A4) ↗
- Collagen alpha-5(IV) chain (COL4A5) ↗
- Collagen alpha-5(VI) chain (COL6A5) ↗
- Collagen alpha-6(IV) chain (COL4A6) ↗
- Collagen alpha-6(VI) chain (COL6A6) ↗
- LamininHYDROLYTIC ENZYME
Laminin hydrolytic enzyme
It's a recombinant truncated form of human plasmin with proteolytic activity against protein components of the vitreous body and the vitreoretinal interface
- Laminin subunit alpha-5 (LAMA5) ↗
- Laminin subunit alpha-1 (LAMA1) ↗
- Laminin subunit alpha-2 (LAMA2) ↗
- Laminin subunit alpha-3 (LAMA3) ↗
- Laminin subunit alpha-4 (LAMA4) ↗
- Laminin subunit beta-1 (LAMB1) ↗
- Laminin subunit beta-2 (LAMB2) ↗
- Laminin subunit beta-3 (LAMB3) ↗
- Laminin subunit beta-4 (LAMB4) ↗
- Laminin subunit gamma-1 (LAMC1) ↗
- Laminin subunit gamma-2 (LAMC2) ↗
- Laminin subunit gamma-3 (LAMC3) ↗
- FibronectinPROTEOLYTIC ENZYME
FN1 proteolytic enzyme
It's a recombinant truncated form of human plasmin with proteolytic activity against protein components of the vitreous body and the vitreoretinal interface
Approval history
- approvedOct 17, 2012
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaOcriplasmin ↗
- NCATS7V6HE3DM5A ↗
- ChEMBLCHEMBL2095222 ↗
Also known as
- jetrea
- jetrea
- microplasmin
- microplasmin
- microplasmin
- microplasmin
- microplasmin
- microplasmin (synthetic human)
- ocriplasmin
- ocriplasmin
- ocriplasmin
- ocriplasmin
- ocriplasmin
- ocriplasmin
- ocriplasmin
- ocriplasmin
- ocriplasmin
- ocriplasmin
- ocriplasmine
- ocriplasmin (genetical recombination)
- recombinant human microplasmin
- vitreosolve
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02747030 | Phase 1 | Dec 1, 2016 | Katholieke Universiteit Leuven |
| NCT02681809 | Phase 2 | Dec 1, 2015 | Oxurion NV. |
| NCT02322229 | Phase 4 | May 1, 2015 | Alcon |
| NCT02035748 | Phase 4 | Apr 1, 2014 | Alcon |
| NCT01889251 | Phase 3 | Jul 1, 2013 | Alcon |
| NCT01429441 | Phase 3 | Oct 1, 2011 | Oxurion NV. |
| NCT01194674 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2011 | National Eye Institute (NEI), National Institutes of Health (NIH) |
| NCT01159665 | Phase 2 | Jul 1, 2010 | Oxurion NV. |
| NCT00986362 | Phase 2 | Feb 1, 2010 | Oxurion NV. |
| NCT00913744 | Phase 2 | Jan 1, 2010 | Oxurion NV. |
| NCT01055535 | Phase 2 | Jan 1, 2010 | Oxurion NV. |
| NCT00996684 | Phase 2 | Oct 1, 2009 | Oxurion NV., University of California, Los Angeles |
| NCT00798317 | Phase 3 | Dec 1, 2008 | Oxurion NV. |
| NCT00781859 | Phase 3 | Dec 1, 2008 | Oxurion NV. |
| NCT00908778 | Phase 3 | Oct 1, 2008 | Hospital La Ceguera, University of Colorado, Denver, Vitreoretinal Technologies, Inc. |
| NCT00664183 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2008 | University of California, Irvine, University of Colorado, Denver, Vitreoretinal Technologies, Inc. |
| NCT00428129 | Phase 2 | Mar 1, 2007 | Bacchus Vascular, Oxurion NV., University of London |
| NCT00435539 | Phase 2 | Feb 1, 2007 | Oxurion NV. |
| NCT00123266 | Phase 2 | Dec 1, 2006 | Johannes Gutenburg University, Oxurion NV. |
| NCT00412958 | Phase 2 | Dec 1, 2006 | Oxurion NV. |
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Oxurion NV. | For profit | 17 | 16 | 2 | 2004 |
| Alcon | For profit | 3 | 3 | 2 | 2013 |
| Katholieke Universiteit Leuven | Academic/Hospital | 3 | 1 | 2 | 2005 |
| University of Colorado, Denver | Academic/Hospital | 2 | 0 | 1 | 2008 |
| Vitreoretinal Technologies, Inc. | For profit | 2 | 2 | 1 | 2008 |
| Bacchus Vascular | For profit | 1 | 0 | 1 | 2007 |
| Hospital La Ceguera | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Johannes Gutenburg University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| National Eye Institute (NEI) | Government | 1 | 0 | 1 | 2011 |
| National Institutes of Health (NIH) | Government | 1 | 1 | 1 | 2011 |
| University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of California, Irvine | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2009 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2007 |
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Oxurion NV. | For profit | MKTG | Oct 17, 2012 |
| Oxurion NV. | For profit | NDA | Oct 17, 2012 |